Equities Analysts Issue Forecasts for Exagen Q1 Earnings

Exagen Inc. (NASDAQ:XGN) – Equities researchers at William Blair issued their Q1 2026 EPS estimates for Exagen in a research report issued on Monday, May 5th. William Blair analyst A. Brackmann forecasts that the company will earn ($0.08) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.04) EPS.

Exagen (NASDAQ:XGN) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.20). The company had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same quarter in the prior year, the firm earned ($0.19) EPS.

A number of other analysts have also commented on XGN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Exagen in a research note on Monday, January 13th. BTIG Research restated a “buy” rating on shares of Exagen in a research report on Wednesday.

Exagen Trading Up 6.4 %

Shares of NASDAQ XGN opened at $6.83 on Wednesday. The business has a fifty day simple moving average of $4.43 and a 200-day simple moving average of $4.06. The company has a market cap of $122.95 million, a price-to-earnings ratio of -7.27 and a beta of 1.50. Exagen has a 12 month low of $1.35 and a 12 month high of $7.20. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Institutional Investors Weigh In On Exagen

Several hedge funds have recently bought and sold shares of XGN. Huntleigh Advisors Inc. increased its holdings in shares of Exagen by 16.8% in the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock valued at $298,000 after purchasing an additional 11,939 shares during the period. Palumbo Wealth Management LLC grew its position in Exagen by 14.4% during the first quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company’s stock valued at $356,000 after purchasing an additional 12,501 shares in the last quarter. Toronto Dominion Bank acquired a new position in Exagen in the 4th quarter valued at approximately $3,655,000. Driehaus Capital Management LLC acquired a new position in Exagen in the 4th quarter valued at approximately $1,716,000. Finally, Northern Trust Corp lifted its position in Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after buying an additional 2,630 shares in the last quarter. 75.25% of the stock is owned by hedge funds and other institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).